Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status

被引:27
作者
Ieiri, I
Kimura, M
He, S
Urae, A
Otsubo, K
Ishizaki, T
机构
[1] Tottori Univ, Dept Hosp Pharm, Fac Med, Yonago, Tottori 6838504, Japan
[2] Kyushu Clin Phamacol Res Clin, Fukuoka, Japan
关键词
tidopidine; CYP2C19; pharmacogenetics; pharmacokinetics; pharmacodynamics;
D O I
10.1097/01213011-200512000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives The aim of this study was to investigate the impact of CYP2C19 polymorphism on the extent of the interaction and on the pharmacokinetics and pharmacodynamics of ticlopidine. Methods Homozygous (hmEMs) and heterozygous extensive metabolizers (htlEMs), and poor metabolizers (PMs, n = 6 each) took an oral dose (20 mg) of omeprazole. After a 1-week washout period, each subject received ticlopidine (200 mg) for 8 days, and ticlopidine pharmacokinetics were studied on days 1 and 7 On day 8, omeprazole was given again and its kinetic disposition was compared with that in the first dose. ADP-induced platelet aggregation was measured as a pharmacodynamic index. Results In contrast to the PMs, whose mean kinetic parameters were not altered by the repeated closings of ticlopidine, an eight- to 10-fold increase in the mean AUC ratio of omeprazole to 5-hydroxyomeprazole was observed in both the EM groups. No significant intergenotypic differences in the pharmacokinetic parameters of ticlopidine were observed, although the accumulation ratio tended to be greater in hmEMs than in PMs (2.4 +/- 0.2 versus 1.7 +/- 0.2). A significantly positive correlation (P=0.031) was observed between the individual percent inhibition of platelet aggregation and AUC(0-24) of ticlopidine regardless of the CYP2C19 polymorphism. Conclusions Ticlopidine is a potent inhibitor for CYP2C19 and may be associated with the phenocopy when CYPC19 substrates are co-administered to EMs. Whether and to what extent CYP2C19 would be involved in the metabolism of ticlopidine remain unanswered from the present in-vivo study.
引用
收藏
页码:851 / 859
页数:9
相关论文
共 39 条
[1]   ANTIPLATELET TREATMENT WITH TICLOPIDINE IN UNSTABLE ANGINA - A CONTROLLED MULTICENTER CLINICAL-TRIAL [J].
BALSANO, F ;
RIZZON, P ;
VIOLI, F ;
SCRUTINIO, D ;
CIMMINIELLO, C ;
AGUGLIA, F ;
PASOTTI, C ;
RUDELLI, G .
CIRCULATION, 1990, 82 (01) :17-26
[2]   HUMAN ANTI-ENDOPLASMIC RETICULUM AUTOANTIBODIES APPEARING IN A DRUG-INDUCED HEPATITIS ARE DIRECTED AGAINST A HUMAN-LIVER CYTOCHROME-P-450 THAT HYDROXYLATES THE DRUG [J].
BEAUNE, P ;
DANSETTE, PM ;
MANSUY, D ;
KIFFEL, L ;
FINCK, M ;
AMAR, C ;
LEROUX, JP ;
HOMBERG, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (02) :551-555
[3]   REDUCTION OF REQUIREMENT FOR LEG VASCULAR-SURGERY DURING LONG-TERM TREATMENT OF CLAUDICANT PATIENTS WITH TICLOPIDINE - RESULTS FROM THE SWEDISH TICLOPIDINE MULTICENTER STUDY (STIMS) [J].
BERGQVIST, D ;
ALMGREN, B ;
DICKINSON, JP .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 1995, 10 (01) :69-76
[4]   Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting - The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study [J].
Bertrand, ME ;
Legrand, V ;
Boland, J ;
Fleck, E ;
Bonnier, J ;
Emmanuelson, H ;
Vrolix, M ;
Missault, L ;
Chierchia, S ;
Casaccia, M ;
Niccoli, L ;
Oto, A ;
White, C ;
Webb-Peploe, M ;
Van Belle, E ;
McFadden, EP .
CIRCULATION, 1998, 98 (16) :1597-1603
[5]   AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL [J].
BORN, GVR .
NATURE, 1962, 194 (4832) :927-&
[6]   Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: Role of peroxidases, cytochromes P450, and monoamine oxidases [J].
Dalvie, DK ;
O'Connell, TN .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) :49-57
[7]   CLINICAL PHARMACOKINETICS OF TICLOPIDINE [J].
DESAGER, JP .
CLINICAL PHARMACOKINETICS, 1994, 26 (05) :347-355
[8]   FUNCTIONALLY THROMBASTHENIC STATE IN NORMAL PLATELETS FOLLOWING THE ADMINISTRATION OF TICLOPIDINE [J].
DIMINNO, G ;
CERBONE, AM ;
MATTIOLI, PL ;
TURCO, S ;
IOVINE, C ;
MANCINI, M .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (02) :328-338
[9]   Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 [J].
Donahue, SR ;
Flockhart, DA ;
Abernethy, DR ;
Ko, JW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) :572-577
[10]  
ELLIS DJ, 1981, THROMB HAEMOSTASIS, V46, P176